Actualización normativa

Descubre el primer estudio que compara iGlarLixi con iDegAsp en pacientes con diabetes tipo 2 no controlados con ADOs. iGlarLixi ofrece mejor control glucémico, menor riesgo de hipoglucemia y beneficio en peso corporal.

Descubre los resultados del Estudio LixiLan-G que evaluó el cambio a iGlarLixi en comparación con ar GLP-1 en pacientes con diabetes tipo 2 inadecuadamente controlados.

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹.

A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹.

A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹.

A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹.

A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.